Yervoy - references pg 2

Article

References: 1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011. 2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8);711-723. 3. Wolchock JD, Weber JS, Hamid O, et al, Ipilimumab efficacy and safety in patients with advanced melanoma: a retrspective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9-14. 4. Data on file. YERV 008. Bristol-Myers Squibb. Princeton, NJ April 2011.

References:
1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8);711-723.
3. Wolchock JD, Weber JS, Hamid O, et al, Ipilimumab efficacy and safety in patients with advanced melanoma: a retrspective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9-14.
4. Data on file. YERV 008. Bristol-Myers Squibb. Princeton, NJ April 2011.

Recent Videos
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
2 experts are featured in this series.
2 experts are featured in this series.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
2 experts are featured in this series.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Related Content
A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC

Tim Cortese
November 17th 2025
Article

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Zanidatamab-Based Regimens Exhibit Improved PFS in Gastroesophageal Cancers

Roman Fabbricatore
November 17th 2025
Article

The safety profile of zanidatamab plus chemotherapy with or without tislelizumab was consistent with the known profiles of each individual agent.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.

This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data

Russ Conroy
November 16th 2025
Article

A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

Tim Cortese
November 15th 2025
Article

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.